Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading ... (visit http://www.Lialda .About Lialda...)

Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal

Date:6/17/2008

About Lialda

Lialda is part of a drug class called aminosalicylates, which contain 5-aminosalicyclic acid (5-ASA). 5-ASA is a well-established drug of choice and often a first-line treatment for UC. Lialda is indicated for the induction of remission in patients with active, mild to moderate UC. The safety and efficacy of Lialda have been established for up to eight weeks. Lialda is the first new formulation in this class to be approved since 2000. Lialda is the only ulcerative colitis treatment that utilizes MMX(R) Technology. Lialda with MMX Technology combines a pH dependent gastro-resistant coating, which delays the release of the medication to the colon (the site of the inflammation in ulcerative colitis), with a tablet core containing mesalamine with hydrophilic and lipophilic components.

Shire has licensed from Giuliani SpA the exclusive rights to develop and commercialize Lialda in the US, Canada, Pacific Rim, and Europe (excluding Italy). Lialda is known as MEZAVANT XL(TM) in the UK and Ireland, and MEZAVANT(R) elsewhere outside of the US. Giuliani SpA retains the development and commercialization rights in Italy. Cosmo Pharmaceuticals SpA, Milan, developed the MMX technology.

For further information please contact:

Investor Relations Clea Rosenfeld (Rest of the World) +44 1256 894 160

Eric Rojas (North America) +1 484 595 8252

Media Blythe Bertolo (GolinHarris on behalf of Shire) +1 312 729 4463

Matthew Cabrey (North America) +1 484 595 8248

Jessica Mann (Rest of the World) +44 1256 894 280

Notes to editors

SHIRE LIMITED

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention
'/>"/>

1

GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Some patients may not need insulin for long-term control of type 2 diabetes
2. New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis
3. Social Security Statement Advises Seniors to Consider Private Long-Term Care Insurance, LTC Agency Reports; Medicare Wont Cover It
4. Treatment at an AASM accredited sleep center improves long-term CPAP compliance
5. Poor sleep a problem in long-term breast cancer survivors
6. Long-term pesticide exposure may increase risk of diabetes
7. Long-term bouts with hay fever worsen ability to breathe through your nose
8. Keane Wins $1.5 Million Electronic Medical Record (EMR) Implementation with Leading Long-Term Care Company
9. Long-term hormone replacement therapy increases breast cancer risk
10. Study concludes no racial disparities in long-term outcomes in recipients of liver transplants
11. Long-term cognitive decline in bypass patients not due to surgery

Post Your Comments:

Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading ...(visit http://www.Lialda .About Lialda...),Health